메이라지티엑스 홀딩스 (MGTX) 주가

메이라지티엑스 홀딩스(MGTX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $13.27 (+1.69%), 시가총액 $0.94B, 52주 최저~최고 $4.63 ~ $11.29.

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital a

핵심 지표

• 현재가: $13.27 (+1.69%)
• 시가총액: $0.94B
• 52주 최저~최고: $4.63 ~ $11.29
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

메이라지티엑스 홀딩스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

메이라지티엑스 홀딩스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.6

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 225.31
• 순이익률: -1.40%
• 영업이익률: 0.35%

자주 묻는 질문